ProKidney (PROK) Director Brian JG Pereira Converts Derivative Securities

What Happened

• Brian JG Pereira, a director of ProKidney Corp. (PROK), reported conversions of derivative securities on 2026-08-04. The filing lists conversions of 81,929 and 675,235 derivative shares (totaling 757,164 shares) acquired at $0. The report also records corresponding disposals of the paired derivative positions.
• All reported transactions show a $0 price, indicating these were non‑cash conversions/exchanges of derivative securities rather than open-market purchases or cash sales.

Key Details

• Transaction date: 2026-08-04. Form filed: 2026-08-06 (appears timely; Form 4 is generally due within two business days).
• Reported acquired amounts: 81,929 and 675,235 shares (total 757,164) at $0. Reported disposals: matching derivative entries for the paired securities (the filing lists disposals corresponding to the same amounts).
• Shares owned after the transaction: not specified in the filing provided.
• Footnotes:
  • F1: Class B Common Stock and Common Units are paired; at the holder’s election (subject to the exchange agreement), each paired Class B share + Common Unit may be exchanged one-for-one for a share of Class A common stock.
  • F2/F3: The Class B shares and Common Units were received in the issuer’s business combination and do not expire.
• Transaction type: conversion of derivative securities (reporting code C). Not an open-market buy or sale of cash consideration.

Context

• Zero-dollar conversions typically reflect an internal exchange or conversion of previously held derivative interests (e.g., Class B shares and paired Common Units) into another equity form, not a market trade. Such transactions are informational rather than a direct cash-based bullish or bearish signal.
• The filing shows paired reporting for the Class B shares and Common Units (per F1), which is why acquisition and disposal lines appear together.